MRK Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
18.1B
+8.9%
16.6B
+2.0%
16.3B
-0.7%
16.4B
-5.1%
17.3B
Cost of Revenue
4.9B
+11.3%
4.4B
+4.8%
4.2B
-24.4%
5.6B
+44.0%
3.9B
Gross Profit
13.2B
+8.0%
12.2B
+1.0%
12.1B
+11.4%
10.8B
-19.2%
13.4B
Operating Expenses
7.6B
-40.6%
12.8B
-17.4%
15.5B
+121.3%
7.0B
+1.2%
6.9B
R&D
4.5B
-53.4%
9.7B
-22.6%
12.6B
+224.0%
3.9B
-8.2%
4.2B
SG&A
2.9B
-0.6%
2.9B
+7.6%
2.7B
-6.8%
2.9B
+10.1%
2.6B
Operating Income
5.6B
+1056.5%
-584000000
+82.8%
-3396000000
-188.2%
3.9B
-40.8%
6.5B
EBITDA
7.6B
+556.8%
1.1B
+168.1%
-1689000000
-125.9%
6.5B
-15.3%
7.7B
Net Income
5.1B
+479.0%
-1337000000
+68.5%
-4243000000
-243.2%
3.0B
-48.8%
5.8B
EPS (Basic)
$2.05
+479.6%
$-0.54
+68.6%
$-1.72
-244.5%
$1.19
-48.7%
$2.32
EPS (Diluted)
$2.04
+477.8%
$-0.54
+68.6%
$-1.72
-244.5%
$1.19
-48.7%
$2.32
Shares (Diluted)
2.5B
+0.3%
2.5B
-0.1%
2.5B
-0.6%
2.5B
-0.5%
2.5B
Merck & (MRK) — Financials